Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
NCT04204928 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2021-08-13
Summary
This is a global, multicenter, open-label pre-approval access program to provide access to pralsetinib (BLU-667) until such time that pralsetinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program.
Conditions
Interventions
- DRUG
-
pralsetinib (BLU-667)
Pralsetinib will be administered orally (PO) at a dose of 400 mg once daily (QD) in continuous 28 day cycles
Sponsors & Collaborators
-
Blueprint Medicines Corporation
lead INDUSTRY
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
NCT04697446 ·Status: UNKNOWN
-
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
NCT07250477 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00918203 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00874107 ·Status: COMPLETED ·Phase: PHASE2
-
Plasma-Adapted First-Line Pembro In NSCLC
NCT04166487 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
NCT00874848 ·Status: COMPLETED ·Phase: PHASE2
-
ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
NCT04241315 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
NCT02492867 ·Status: COMPLETED ·Phase: NA
-
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
NCT06262321 ·Status: RECRUITING ·Phase: PHASE2
-
Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer
NCT02974933 ·Status: UNKNOWN ·Phase: PHASE2
-
Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura
NCT00601848 ·Status: TERMINATED ·Phase: PHASE2
-
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
NCT03829436 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Pembro+Chemo in Brain Mets
NCT04964960 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
NCT06640413 ·Status: RECRUITING ·Phase: PHASE1
-
Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC
NCT02799862 ·Status: COMPLETED
-
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
NCT04914897 ·Status: TERMINATED ·Phase: PHASE2
-
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen
NCT02475382 ·Status: NO_LONGER_AVAILABLE
-
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
NCT05364645 ·Status: WITHDRAWN ·Phase: PHASE2
-
Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy
NCT03951012 ·Status: TERMINATED
-
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
NCT01820325 ·Status: TERMINATED ·Phase: PHASE1
-
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I/II Calcitriol in Lung Cancer
NCT00794547 ·Status: TERMINATED ·Phase: PHASE1/PHASE2